By Eili Cordova
The matriarch of the Kardashian-Jenner clan revealed that she tried using the weight-loss drug before she became famous, but the side effects were so severe that she had to call her doctor.
Kris Jenner, known for her impeccable management of her daughters’ fame and her own media empire, recently confessed that she tried Ozempic, the popular type 2 diabetes medication that many celebrities use to lose weight, but the experience ended up being a resounding failure.
In a conversation for the SHE MD podcast, the 69-year-old businesswoman said that she became seriously ill after receiving the injection. “I didn’t make an Ozempic. I tried it. We tried it once when no one knew what period, and it made me feel very bad,” he stated bluntly.
Jenner reported that the discomfort was so intense that she could not continue with her work routine. “I called my doctor and said, ‘I can’t work anymore. I can’t, I’m very sick. I’m nauseous,'” he recalled. Faced with the emergency, her doctor responded: “Okay, okay, let’s try something else.”
Kim Kardashian’s mother explained that, after that episode, she and her doctor investigated other alternatives at different health centers. Finally, they completely ruled out the use of GLP-1 drugs such as Ozempic and opted for a treatment with peptide injections, which Jenner said were much better suited to his body.
While figures such as tennis player Serena Williams have publicly defended the use of GLP-1 for weight control, Kris Jenner prefers to stay away from these injections. Her priority, she says, is to undergo blood tests every three months to keep her hormones balanced, care that she considers essential for women’s health after the age of forty-five.
“I got really sick with it,” Jenner concluded, making it clear that, at least in the case of Ozempic, she is not planning to use it.
Continue reading:
· Kris Jenner breaks the silence about her surgeries and facelift: “My nose is the only right thing”
· How did Kris Jenner celebrate her 70th birthday?
· Kris Jenner surprised with an unexpected peek change
